CLINICS, DIAGNOSTICS AND TREATMENT OF NEUROAIDS
https://doi.org/10.25016/2541-7487-2013-0-2-36-42
Abstract
Because of HIV epidemic progression, the study of psychophysiological state of patients is very important for the purpose of adequate treatment, rehabilitation and social actions. This review is devoted to questions of the morphology, clinics, diagnosis and treatment of neuroAIDS. It's noted that the objective estimation of professional suitability of patients requires further study of mechanisms of intellectual mental disturbances. The study of HIV neurocognitive disorders brings us to the biopsychosocial model of treatment, which enables a holistic approach to each patient, with assessment of his individual personality characteristics, severity of physical illness, clinical picture of psychopathology, as well as interpersonal and social interaction.
About the Authors
I. M. Ulyukin
Militari Medical Academy named after S.M. Kirov, St. Petersburg
Russian Federation
Russian Federation
Yu. I. Bulankov
Militari Medical Academy named after S.M. Kirov, St. Petersburg
Russian Federation
Russian Federation
V. N. Bolekhan
Militari Medical Academy named after S.M. Kirov, St. Petersburg
Russian Federation
Russian Federation
References
1. Pokrovskii V.V. [et al.]. VICh-infektsiya : informatsionnyi byulleten' № 36 [HIV infection: the newsletter N 36.]. Moskva. 2012. 53 p. (In Russ.)
2. Leonova O.N., Stepanova E.V., Vinogradova T.N. Porazheniya nervnoi sistemy u bol'nykh s VICh-infektsiei [Neurologic pathology in HIV-infected patients]. Mediko-biologicheskie i sotsial'nopsikhologicheskie problemy bezopasnosti v chrezvychaynykh situatsiyakh [Medical-Biological and Socio-Psychological Problems of Safety in Emergency Situations]. 2012. N 3. Pp. 44–51. (In Russ.)
3. Sokolova L.P. Osobennosti neirometabolizma i perfuzii golovnogo mozga s pozitsii patogeneticheskikh mekhanizmov formirovaniya dodementnykh kognitivnykh rasstroistv razlichnogo geneza [Features of neurometabolism and cerebral perfusion in terms of pathogenetic mechanisms of formation of pre-dementia cognitive disorders of various origins]. Moskva. 2012. 50 p. (In Russ.)
4. Trofimova T.N., Belyakov N.A. Mnogolikaya neiroradiologiya VICh-infektsii [The Many Faces of HIV Neuroradiology]. Luchevaya diagnostika i terapiya [Diagnostic radiology and radiotherapy]. 2010. Vol. 1, N 3. Pp. 5–11. (In Russ.)
5. Ulyukin I.M., Bolekhan V.N., Bulan'kov Yu.I. Voprosy diagnostiki somato-psikhologicheskogo sostoyaniya bol'nykh VICh-infektsiei molodogo vozrasta [Questions of diagnosing somatic and psychological state of young patients with HIV infection]. Vestnik Rossiiskoi Voenno-meditsinskoi akademii [Bulletin of Russian Military medical Academy]. 2012. N 2. Pp. 84–89. (In Russ.)
6. Gurskaya O.E. [et al.]. Elektrofiziologicheskie metody v diagnostike subklinicheskikh kognitivnykh narushenii u VICh-infitsirovannykh bol'nykh [Electrophysiological methods in the diagnosis of subclinical cognitive impairment in HIV-infected patients]. Zhurnal infektologii [Journal of infectology]. 2012. Vol. 3, N 4. Pp. 80–87. (In Russ.)
7. Castelo J.M. [et al.]. Altered hippocampal-prefrontal activation in HIV patients during episodic memory encoding. Neurology. 2006. Vol. 66, N 11. Pp. 1688–1695.
8. Shiramizu B. [et al.]. Amount of HIV DNA in peripheral blood mononuclear cells is proportional to the severity of HIV-associated cognitive disorders. J. Neuropsychiatry Clin. Neurosci. 2009. Vol. 21, N 1. Pp. 68–74.
9. Brennan T.P. [et al.]. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J. Virol. 2009. Vol. 83, N 17. Pp. 8470–8481.
10. S.A. Spector [et al.]. APOE epsilon4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIV-infected plasma donors. AIDS. 2010. Vol. 24, N 10. Pp. 1471–1479.
11. Levine A.J. [et al.]. CCL3 genotype and current depression increase risk of HIV-associated dementia. Neurobech. HIV Med. 2009. N 1. Pp. 1–7.
12. Bhaskaran K. [et al.]. Changes in the incidence and predictors of human immunodeficiency virus associated dementia in the era of highly active antiretroviral therapy. Ann. Neurol. 2008. Vol. 63, N 2. Pp. 213–221.
13. Lee K. [et al.]. Clinical outcomes and immune benefits of antiepileptic drug therapy in HIV/AIDS. BMC Neurol. 2010. N 10. Pp. 44–48.
14. Dhillon N.K. [et al.]. Cocaine-mediated enhancement of virus replication in macrophages: implications for human immunodeficiency virus-associated dementia. J. Neurovirol. 2007. Vol. 13, N. 6. P. 483–495.
15. Chana G. [et al.]. Cognitive deficits and degeneration of interneurons in HIVR methamphetamine users. Neurology. 2006. Vol. 67, N 8. Pp. 1486–1489.
16. Woods S.P. [et al.]. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neurophysiol. Rev. 2009. Vol. 19, N 2. Pp. 152–168.
17. Caragounis E.C. [et al.]. Comparison of HIV-1 pop and env sequences of blood, CSF, brain and spleen isolates collected ante-mortem and postmortem. Acta Neurol. Scand. 2008. Vol. 117, N 2. Pp. 108–116.
18. Cysique L.A., Maruff P., Brew B.J. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus infected / acquired immunodeficiency syndrome (HIV/AIDS) patients across pre and post highly active antiretroviral therapy eras: a combined study of two cohorts. J. Neurovirol. 2004. Vol. 10, N 6. Pp. 350–357.
19. A. Minagar [et al.]. Diagnostics for NeuroAIDS: present and future. Molec. Diagn. Ther. 2008. Vol. 12, N 1. Pp. 25–43.
20. Samikkannu T. [et al.]. Differential regulation of indoleamine-2, 3 – dioxygenase (IDO) by HIV type 1 clade B and C Tat protein. AIDS Res. Hum. Retroviruses. 2009. Vol. 25, N 3. Pp. 329–335.
21. Wu Y. [et al.]. Diffusion alterations in corpus callosum of patients with HIV. Am. J. Neuroradiol. 2006. Vol. 27, N 3. Pp. 656–660.
22. Kuczenski R. [et al.]. Escalating dose-multiple binge methamphetamine exposure results in degeneration of the neocortex and limbic system in the rat. Exp. Neurol. 2007. Vol. 207, N 1. Pp. 42–51.
23. Tatro E.T. [et al.]. Evidence for alteration of gene regulatory networks through microRNAs of the HIV-infected brain: novel analysis of retrospective cases. PLoS One. 2010. N 5. e10337. Doi: 10.1371/journal.pone.0010337.
24. Churchill M.J. [et al.]. Extensive astricyte infection is prominent in human immunodeficiency virus-associated dementia. Ann. Neurol. 2009. Vol. 66, N 2. Pp. 253–258.
25. Pfefferbaum A. [et al.]. Frontostriatal fiber bundle compromise in HIV infection without dementia. AIDS. 2009. Vol. 23, N 15. Pp. 1977–1985.
26. Valcour V.G. [et al.]. HIV DNA and cognition in Thai longitudinal HAART initiation cohort: SEARCH001 cohort study. Neurol. 2009. Vol. 72, N 11. Pp. 992–998.
27. Scheer S. [et al.]. HIV is hyperendemic among men who have sex with men in San Francisco: 10-year trends in HIV incidence. HIV prevalence, sexually transmitted infections and sexual risk behaviour. Sex. Transm. Infect. 2008. Vol. 84, N 6. Pp. 493–498.
28. Eugenin E.A. [et al.]. Human immunodeficiency virus infection of human astrocytes disrupts blood-brain barrier integrity by a gap junction-dependent mechanism. J. Neurosci. 2011. Vol. 31, N 26. Pp. 9456–9465.
29. Gaskill P.J. [et al.]. Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: a bridge between HIV-associated neurologic disorders and drug abuse. Am. J. Pathol. 2009. Vol. 175, N 3. Pp. 1148–1159.
30. McArthur J.C. [et al.]. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann. Neurol. 2010. Vol. 67, N 6. Pp. 699–714.
31. Eden A. [et al.]. Immune activation of the central nervous system is still present after > 4 years of effective highly active antiretroviral therapy. J. Infect. Dis. 2007. Vol. 196, N 12. Pp. 1779–1983.
32. Venkataramana A. [et al.]. Immune reconstruction inflammatory syndrome in the CNS of HIVinfected patients. Neurology. 2006. Vol. 67, N. 3. Pp. 383–388.
33. Marra C.M. [et al.]. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009. Vol. 23, N 11. Pp. 1359–1366.
34. Khanlou N. [et al.]. Increased frequency of alpha-synuclein in the substantia nigra in human immunodeficiency virus infection. J. Neurovirol. 2009. Vol. 15, N 2. Pp. 131–138.
35. Kim M.T., Hill M.N. Validity of self-report of illicit drug use in young hypersensitive urban African-American males // Addict. Beh. – 2003. – Vol. 28, N 4. – Pp. 795–802.
36. Descamps M. [et al.]. Magnetic resonance imaging and spectroscopy of the brain in HIV disease. J. HIV Ther. 2008. Vol. 13, N 3. Pp. 55–58.
37. G. Schiffito [et al.]. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS. 2007. Vol. 21, N 14. Pp. 1877–1886.
38. Power C. [et al.]. NeuroAIDS: an evolving epidemic. Can. J. Neurol. Sci. 2009. Vol. 36, N 3. Pp. 285–295.
39. Perdices M., Cooper D.A. Simple and choice reaction in patients with human immunodeficiency virus infection. Ann. Neurol. 1989. Vol. 25, N 5. Pp. 460–467.
40. Price R.W., Brew B.J. The AIDS dementia complex. J. Inf. Dis. 1988. Vol. 158, N 5. Pp. 1079–1083.
41. Pulliam L. HIV regulation of amyloid beta production. J. Neuroimmune Pharmacol. 2009. Vol. 4, N 2. Pp. 213–217.
42. Cole M.A. et al.]. Relationship between psychiatric status and frontal-subcortical systems in HIV-infected individuals. J. Int. Neuropsychol. Soc. 2007. Vol. 13, N 3. Pp. 549–554.
43. Nguyen V.-K. [et al.]. Remedicalizing an epidemic: from HIV treatment as prevention to HIV treatment is prevention. AIDS. 2011. Vol. 25, N 3. Pp. 291–293.
44. Hightower G.K. [et al.]. Select resistance-associated mutations in blood are associated with lower CSF viral load and better neuropsychological performance. Virology. 2009 Vol. 394, N 2. Pp. 243–248.
45. Richman D.D. [et al.] The challenge of finding a cure for HIV-infection. Science. 2009. Vol. 323, N 5919. Pp. 1304–1307.
46. Robertson K. [et al.]. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007. Vol. 21, N 14. Pp. 1915–1921.
47. Mahajan S.D. [et al.]. Tihgt junction regulation by morphine and HIV-1 Tat modulates bloodbrain barrier permeability. J. Clin. Immunol. 2008. Vol. 28, N 5. Pp. 528–541.
48. Antinori A. [et al.]. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007. Vol. 69, N 18. Pp. 1789–1799.
49. Letendre S.L. [et al.]. Validation of the CNS Penertation-Effectiveness (CPE) Score for quantifying anti-retroviral penetration into the central nervous system. Arch. Neurol. 2008. Vol. 65, N 1. Pp. 65–70.
50. Chen Y. [et al.]. White matter abnormalities by diffusion tensor imaging in non-demented and demented HIV+ patients. Neuroimage. 2009. Vol. 47, N 4. Pp. 1154–1162.
Review
For citations:
Ulyukin I.M., Bulankov Yu.I., Bolekhan V.N. CLINICS, DIAGNOSTICS AND TREATMENT OF NEUROAIDS. Medicо-Biological and Socio-Psychological Problems of Safety in Emergency Situations. 2013;(2):36-42. (In Russ.) https://doi.org/10.25016/2541-7487-2013-0-2-36-42
Views:
2868
Email this article 